A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists.
about
The effect of angiotensin II receptor blockers on hyperuricemiaRole and therapeutic potential of G-protein coupled receptors in breast cancer progression and metastasesIntermittent losartan administration triggers cardiac post-conditioning in isolated rat hearts: role of BK2 receptorsAngiotensin receptor type 2 activation induces neuroprotection and neurogenesis after traumatic brain injury.Management of Hypertension Using Olmesartan Alone or in CombinationDiabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15,990 patients.Preventing leptin resistance by blocking angiotensin II AT1 receptors in diet-induced obese rats.Suppression of adrenal βarrestin1-dependent aldosterone production by ARBs: head-to-head comparison.The application of solid-state NMR spectroscopy to study candesartan cilexetil (TCV-116) membrane interactions. Comparative study with the AT1R antagonist drug olmesartanEffects of candesartan, an angiotensin II receptor type I blocker, on atrial remodeling in spontaneously hypertensive rats.An integrative genome-wide transcriptome reveals that candesartan is neuroprotective and a candidate therapeutic for Alzheimer's diseaseActivation of MyD88-dependent TLR1/2 signaling by misfolded α-synuclein, a protein linked to neurodegenerative disorders.Immunopathogenesis of olmesartan-associated enteropathy.International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].Angiotensin II type 1 receptor blockers increase tolerance of cells to copper and cisplatin.Neurorestoration after traumatic brain injury through angiotensin II receptor blockageComparison of Efficacy of Long-term Oral Treatment with Telmisartan and Benazepril in Cats with Chronic Kidney Disease.Changeover Trial of Azilsartan and Olmesartan Comparing Effects on the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension after Cardiac Surgery (CHAOS Study).Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels.Brain and retinal microglia in health and disease: an unrecognized target of the renin-angiotensin system.Current status of renin-aldosterone angiotensin system-targeting anti-hypertensive drugs as therapeutic options for Alzheimer's disease.AT1 antagonists: a patent review (2008 - 2012).Therapeutic implications of peptide interactions with G-protein-coupled receptors in diabetic vasculopathy.Should losartan be administered following brain injury?Neuroprotective effects of angiotensin receptor blockers.Selectivity of pharmacological tools: implications for use in cell physiology. A review in the theme: Cell signaling: proteins, pathways and mechanisms.Novel RAAS agonists and antagonists: clinical applications and controversies.Are microRNAs the Molecular Link Between Metabolic Syndrome and Alzheimer's Disease?Small molecule and peptide therapies for chronic heart failure: a patent review (2011 - 2014).Angiotensin II centrally induces frequent detrusor contractility of the bladder by acting on brain angiotensin II type 1 receptors in rats.On the different experimental manifestations of two-state 'induced-fit' binding of drugs to their cellular targetsCentral-acting therapeutics alleviate respiratory weakness caused by heart failure-induced ventilatory overdrive.Neurovascular and Cognitive failure in Alzheimer's Disease: Benefits of Cardiovascular Therapy.Novel insight into the dangerous connection between diabetes and heart failure.Inhibition or deletion of angiotensin II type 1 receptor suppresses elastase-induced experimental abdominal aortic aneurysms.Angiotensin II type 1 receptor blockade suppresses H2O2-induced retinal degeneration in photoreceptor cells.The Model for End-stage Liver Disease score is potentially a useful predictor of hyperkalemia occurrence among hospitalized angiotensin receptor blocker users.Novel Anti-fibrotic Therapies.Population Pharmacokinetic Modeling of Olmesartan, the Active Metabolite of Olmesartan Medoxomil, in Patients with Hypertension.The brain renin-angiotensin system plays a crucial role in regulating body weight in diet-induced obesity in rats.
P2860
Q26777082-D8F3AB06-E9A8-46D5-A077-572DC84C4C0BQ28084420-C0EABE91-217C-4843-ACAB-53E422C717E0Q28539671-15FD639A-5BA9-4B3A-8931-F31B15FEAF42Q30585823-23692D54-23A0-4A6D-972D-5DA1F4B1DD64Q33734043-FC925E7C-D6FB-48A3-A624-67A390B368AAQ34312115-28123991-AF7D-4100-B51A-F53C950B7C45Q34994537-773FEF2B-8DF9-400F-98BA-0CED73023E57Q35024828-9563F2B3-9B52-4FCC-91BA-BF0B648F0791Q35063904-1008E210-4153-4BE3-BDFB-7FCB6D28C5B0Q35294169-F4EE96E2-0862-4EC0-B273-AB707F688383Q35907609-E399F0D3-962A-4EB1-9FD4-46E3CEF32606Q36148314-BACC1734-C470-4C10-8064-89A9D4D6EE12Q36225350-D931F08E-F90F-4E43-A753-AA4BEBD25588Q36241932-0071DD37-DCF4-4C25-B516-6FF67E4D58BBQ36327667-FBD936DC-E999-4515-8025-82A358EA0DB1Q36515931-CFDE7D2B-BC7C-41F1-A48D-03FFE503652FQ36975699-75736804-C719-491D-88EA-14690E5B05DAQ37010254-1D9659B0-CF09-4F1A-ACA2-E6BC31C037F7Q37250548-ECBBB86B-60A3-496E-8578-A1DEAA0646EBQ38100285-F40F2A5A-924B-428C-90E1-6773F3965CD9Q38116974-F2E39741-3335-4652-8D4C-4287F119C062Q38130756-28610AAF-2413-40EC-B704-EBD602046671Q38196857-C255B013-7535-48BF-8E63-342F1C580457Q38262865-967D22BD-C0C3-4F61-B3A4-86165BAC7586Q38264237-56850C09-8C41-4FEC-B17F-480547FB2D6EQ38336214-70E2046A-71B7-44B5-B2E1-6AB336B5C147Q38349798-78A37A97-CE1F-4598-B403-BD31C886E86AQ38481462-527AAF5E-50F3-449E-BFE3-AE3497541840Q38546917-000A6B93-1563-4760-B8BE-36AE8E87A88FQ38608090-5B15F134-5093-4816-9CD0-3788BF810587Q38710840-3A4AD2E5-B17A-464F-B81D-99A865FE4F23Q38780056-26127B11-B441-444E-BFA7-6AC54B14122DQ38781022-4FBBF717-A7E4-4779-A861-CF83C9E44FFDQ38806574-F2EBCD11-1C79-40B0-8F36-B796FF0B3A86Q38824336-7E7473E9-C839-4D8D-93B7-A9A7E62FF6BEQ38937328-A55D7C6D-E0B0-4247-8E8D-3EE4495DA261Q39110921-AAF7722D-A7C9-4F22-8680-4924DFDDAC31Q39377055-AC03E3EC-9BC0-4838-BEDA-31C6BCF18383Q39479847-5D6EC115-C830-48CC-A6BB-805382BACFACQ40559527-75C4E56E-52FD-40FA-A9ED-512D77AE7448
P2860
A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
A systematic comparison of the ...... I type 1 receptor antagonists.
@en
type
label
A systematic comparison of the ...... I type 1 receptor antagonists.
@en
prefLabel
A systematic comparison of the ...... I type 1 receptor antagonists.
@en
P2093
P356
P1476
A systematic comparison of the ...... I type 1 receptor antagonists.
@en
P2093
Carolyn Foster
Hans R Brunner
Lisheng Liu
P304
P356
10.1124/PR.112.007278
P577
2013-03-13T00:00:00Z